Upstream Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-62.81	-20.54	-23.87
Depreciation & Amortization	0.09	0.06	0.01
Loss (Gain) From Sale of Investments	-1.66	-1.26	-
Stock-Based Compensation	6	3.43	1.28
Other Operating Activities	-2.68	-15.31	0.15
Change in Accounts Receivable	-0.52	0.31	-0.41
Change in Accounts Payable	2.02	1.28	0.46
Change in Other Net Operating Assets	0.37	-5.9	3.36
Operating Cash Flow	-59.17	-37.93	-19.02
Capital Expenditures	-0.51	-0.14	-0.08
Investment in Securities	-58.97	-82.7	-
Investing Cash Flow	-59.49	-82.84	-0.08
Issuance of Common Stock	272.88	0.12	-
Other Financing Activities	-3.97	-	-0.04
Financing Cash Flow	418.91	129.55	9.96
Net Cash Flow	300.25	8.78	-9.14
Free Cash Flow	-59.68	-38.07	-19.1
Free Cash Flow Margin	-2518.27%	-1599.58%	-1576.15%
Free Cash Flow Per Share	-4.36	-12.89	-6.82
Levered Free Cash Flow	-40.98	-25.96	-
Unlevered Free Cash Flow	-40.98	-25.96	-
Change in Net Working Capital	-2.04	4.23	-

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q